Bristol Myers Squibb (CELG-RI) Interest & Investment Income (2012 - 2025)

Bristol Myers Squibb (CELG-RI) has reported Interest & Investment Income for 7 consecutive years, with $566.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Interest & Investment Income fell 12.65% year-over-year to $566.0 million; the TTM figure through Dec 2025 stood at $566.0 million (down 12.65% YoY), while the FY2025 annual figure was $566.0 million, down 12.65% from the prior year.
• Interest & Investment Income eased to $566.0 million in Q4 2025 per CELG-RI's latest filing, from $648.0 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $768.0 million in Q4 2021 and bottomed at $566.0 million in Q4 2025.
• Historically, Interest & Investment Income has averaged $668.6 million across 5 years, with a median of $648.0 million in 2024.
• Annual changes were most pronounced in 2022 — Interest & Investment Income decreased 18.88% — and 2023, when it gained 18.46%.
• Bristol Myers Squibb's Interest & Investment Income stood at $768.0 million in 2021, then fell by 18.88% to $623.0 million in 2022, then grew by 18.46% to $738.0 million in 2023, then dropped by 12.2% to $648.0 million in 2024, then decreased by 12.65% to $566.0 million in 2025.
• Business Quant data shows CELG-RI's Interest & Investment Income at $566.0 million in Q4 2025, $648.0 million in Q4 2024, and $738.0 million in Q4 2023.